Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era


Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the motor neurons, which results in weakness and atrophy of voluntary skeletal muscles. Treatments do not modify the disease trajectory effectively, and only modestly improve survival. A complex interaction between genes, environmental exposure and impaired molecular pathways contributes to pathology in patients with ALS. Epigenetic mechanisms control the hereditary and reversible regulation of gene expression without altering the basic genetic code. Aberrant epigenetic patterns—including abnormal microRNA (miRNA) biogenesis and function, DNA modifications, histone remodeling, and RNA editing—are acquired throughout life and are influenced by environmental factors. Thus, understanding the molecular processes that lead to epigenetic dysregulation in patients with ALS might facilitate the discovery of novel therapeutic targets and biomarkers that could reduce diagnostic delay. These achievements could prove crucial for successful disease modification in patients with ALS. We review the latest findings regarding the role of miRNA modifications and other epigenetic mechanisms in ALS, and discuss their potential as therapeutic targets.

DOI: 10.1038/nrneurol.2015.57
Citations per Year

841 Citations

Semantic Scholar estimates that this publication has 841 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{PaezColasante2015AmyotrophicLS, title={Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era}, author={Ximena Paez-Colasante and Claudia Figueroa-Romero and Stacey A. Sakowski and Stephen A. Goutman and Eva L. Feldman}, journal={Nature Reviews Neurology}, year={2015}, volume={11}, pages={266-279} }